JPWO2021129672A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021129672A5
JPWO2021129672A5 JP2022539176A JP2022539176A JPWO2021129672A5 JP WO2021129672 A5 JPWO2021129672 A5 JP WO2021129672A5 JP 2022539176 A JP2022539176 A JP 2022539176A JP 2022539176 A JP2022539176 A JP 2022539176A JP WO2021129672 A5 JPWO2021129672 A5 JP WO2021129672A5
Authority
JP
Japan
Prior art keywords
seq
antibody
fgfr2b
antibody according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022539176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023508174A5 (https=
JP7692419B2 (ja
JP2023508174A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/138659 external-priority patent/WO2021129672A1/en
Publication of JP2023508174A publication Critical patent/JP2023508174A/ja
Publication of JP2023508174A5 publication Critical patent/JP2023508174A5/ja
Publication of JPWO2021129672A5 publication Critical patent/JPWO2021129672A5/ja
Application granted granted Critical
Publication of JP7692419B2 publication Critical patent/JP7692419B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022539176A 2019-12-24 2020-12-23 新規抗ＦＧＦＲ２ｂ抗体 Active JP7692419B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019127904 2019-12-24
CNPCT/CN2019/127904 2019-12-24
PCT/CN2020/138659 WO2021129672A1 (en) 2019-12-24 2020-12-23 Novel anti-fgfr2b antibodies

Publications (4)

Publication Number Publication Date
JP2023508174A JP2023508174A (ja) 2023-03-01
JP2023508174A5 JP2023508174A5 (https=) 2024-01-05
JPWO2021129672A5 true JPWO2021129672A5 (https=) 2024-01-05
JP7692419B2 JP7692419B2 (ja) 2025-06-13

Family

ID=76575671

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022539176A Active JP7692419B2 (ja) 2019-12-24 2020-12-23 新規抗ＦＧＦＲ２ｂ抗体

Country Status (11)

Country Link
US (1) US20230052680A1 (https=)
EP (1) EP4081547A4 (https=)
JP (1) JP7692419B2 (https=)
KR (1) KR20220119144A (https=)
CN (1) CN114846029A (https=)
AR (1) AR120886A1 (https=)
AU (1) AU2020412088A1 (https=)
CA (1) CA3160812A1 (https=)
MX (1) MX2022007961A (https=)
TW (1) TWI861326B (https=)
WO (1) WO2021129672A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230052256A1 (en) * 2019-12-24 2023-02-16 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
AU2023243773A1 (en) * 2022-03-28 2024-10-24 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Novel anti-fgfr2 antibodies.
WO2024199362A1 (en) * 2023-03-31 2024-10-03 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Novel anti-FGFR2 antibodies
WO2024222912A1 (zh) * 2023-04-28 2024-10-31 武汉人福创新药物研发中心有限公司 抗FGFR2b单抗
CN118994393A (zh) * 2023-05-19 2024-11-22 广东东阳光药业股份有限公司 一种抗fgfr2抗体及其应用
TW202540177A (zh) * 2023-11-14 2025-10-16 大陸商蘇州創勝醫藥集團有限公司 抗－ＦＧＦＲ２ｂ免疫偶聯物及其於治療癌症的用途
WO2025130905A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体-药物缀合物及其应用
WO2025146131A1 (en) * 2024-01-05 2025-07-10 Beigene, Ltd. ANTI-FGFR2b ANTIBODIES, CONJUGATES AND METHODS OF USE
CN120424212A (zh) * 2024-01-26 2025-08-05 上海安领科生物医药有限公司 抗FGFR2b抗体及抗体药物偶联物
CN118772279B (zh) * 2024-06-28 2025-03-25 北京普利米特生物科技有限公司 抗FGFR2b抗体或其抗原结合片段及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
PL2365828T3 (pl) * 2008-11-07 2015-04-30 Galaxy Biotech Llc Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów
CN105263962B (zh) * 2013-03-19 2019-12-31 北京盛诺基医药科技股份有限公司 抗体及用于治疗与雌激素受体相关疾病的方法
PH12021552742A1 (en) * 2013-08-01 2022-05-23 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
CN103757026B (zh) * 2013-12-20 2017-04-05 广州圣露生物技术有限公司 FGFR2b胞外段的基因序列、多肽及其应用
US20170145103A1 (en) * 2015-11-23 2017-05-25 Five Prime Therapeutics, Inc. Predicting response to cancer treatment with fgfr2 inhibitors
SG10202112636SA (en) * 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment

Similar Documents

Publication Publication Date Title
CN115052892A (zh) 抗ccr8单克隆抗体及其用途
CN101090913B (zh) 抗生腱蛋白c的抗体
JP2021106617A5 (https=)
CN112566662A (zh) 针对cd47的阻断抗体及其使用方法
CN110627906A (zh) 抗pd-l1/4-1bb双特异性抗体及其用途
JP7820383B2 (ja) グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
BR112021010402A2 (pt) Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
CN114040925B (zh) 抗SIRPα单克隆抗体及其用途
JP2019534705A5 (https=)
IL273389B1 (en) New anti-CD19 antibodies
KR20220024211A (ko) 항-cd47 항체 및 그것의 사용
CN121909212A (zh) 抗cdh17抗体及其用途
JPWO2021129672A5 (https=)
JPWO2021129655A5 (https=)
WO2022175481A1 (en) Vegfa-binding molecules
JP2025520692A (ja) 抗ｓｌｃ３４ａ２モノクローナル抗体およびその使用
JPWO2021129656A5 (https=)
JPWO2022042719A5 (https=)
CN120535623B (zh) Cdh17结合分子及其用途
CN120271715A (zh) 抗体及其药物偶联物和用途
KR20250160321A (ko) 항-메소텔린 항체 및 이의 용도
HK40080157A (en) Anti-gprc5d monoclonal antibodies and uses thereof
TW202313690A (zh) 一種抗b7-h4抗體及其製備方法和應用
CN116761887A (zh) 靶向SIRPα和PD-L1的双特异性抗体
CN120379695A (zh) 使用Multabody治疗化疗抗性肿瘤